Rolling forward its mid-term guidance with strong 2024 performance as the base year, Novartis now expects to grow sales at +5% CAGR 2024-2029. The company remains on track to deliver core operating ...

Basel, November 19, 2024 – Novartis has ranked first in the 2024 Access to Medicine Index (ATMI) report published today, highlighting the company’s leadership in improving access to medicines around ...

Acquisition of Kate Therapeutics enhances and strengthens Novartis strategic priorities in gene therapy and neuroscience innovation Transaction includes enabling technology platforms and therapeutic ...

Novartis has climbed three places to secure the top position in the 2024 Access to Medicine Index. The Access to Medicine Foundation (ATMI) report highlights Novartis' leading role in research and ...

Originally from Colombia, I trained as a Biologist and Microbiologist before moving to Brazil for academic research. After earning my Masters and starting a PhD in Neglected Tropical Diseases, I ...

Explore opportunities with Novartis and Sandoz below. For additional roles with Novartis Gene Therapies (formerly AveXis) visit the GTx Career Search.

An International, Prospective, Open-label, Multi-center, Randomized Phase III Study Comparing Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) Versus Observation to Delay Castration or Disease ...

All compounds are either investigational or being studied for (a) new use(s). Efficacy and safety have not been established. There is no guarantee that they will become commercially available for the ...

An Open Label, Multi-center Asciminib Roll-over Study to Assess Long-term Safety in Patients Who Have Completed a Novartis Sponsored Asciminib Study and Are Judged by the Investigator to Benefit From ...